Voxelotor and albuminuria in adults with sickle cell anaemia.
作者信息
Han Jin, Molokie Robert E, Hussain Faiz, Njoku Franklin, Gordeuk Victor R, Saraf Santosh L
机构信息
Division of Hematology and Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA.
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
出版信息
Br J Haematol. 2022 Jun;197(5):e63-e64. doi: 10.1111/bjh.18076. Epub 2022 Feb 14.
Abstract
摘要
相似文献
1
Voxelotor and albuminuria in adults with sickle cell anaemia.患有镰状细胞贫血的成年人中的瓦洛托（voxelotor）与蛋白尿
Br J Haematol. 2022 Jun;197(5):e63-e64. doi: 10.1111/bjh.18076. Epub 2022 Feb 14.
2
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.伏打诺特治疗青少年和成年镰状细胞病患者（HOPE）的研究：一项国际、随机、双盲、安慰剂对照的 3 期临床试验的长期随访结果。
Lancet Haematol. 2021 May;8(5):e323-e333. doi: 10.1016/S2352-3026(21)00059-4. Epub 2021 Apr 7.
3
The efficacy of voxelotor, 900 mg in patients with sickle cell anaemia: A meta-analysis of the randomised controlled trials.罗沙司他治疗肾性贫血的有效性和安全性的系统评价和 Meta 分析
Int J Clin Pract. 2021 Jun;75(6):e13967. doi: 10.1111/ijcp.13967. Epub 2021 Jan 15.
4
Voxelotor in sickle cell disease.用于镰状细胞病的voxelotor
Am J Hematol. 2022 Jun 1;97(6):830-832. doi: 10.1002/ajh.26549. Epub 2022 Apr 8.
5
Voxelotor for the Treatment of Sickle Cell Disease.伏打络索治疗镰状细胞病。
Nurs Womens Health. 2020 Jun;24(3):233-237. doi: 10.1016/j.nwh.2020.03.003. Epub 2020 May 6.
6
Voxelotor for the treatment of sickle cell disease in pediatric patients.用于治疗儿科患者镰状细胞病的武利尤单抗。
Expert Rev Hematol. 2022 Jun;15(6):485-492. doi: 10.1080/17474086.2022.2082408. Epub 2022 Jun 7.
7
Multi-organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease.一名重症镰状细胞病患者因突然停用伏氯托而继发多器官功能障碍。
Am J Hematol. 2022 Aug;97(8):E318-E320. doi: 10.1002/ajh.26631. Epub 2022 Jun 24.
8
Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.在立即输血不安全的情况下， urgently 使用 voxelotor 治疗镰状细胞病。
Eur J Haematol. 2022 Nov;109(5):586-589. doi: 10.1111/ejh.13830. Epub 2022 Aug 10.
9
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.一项针对镰状细胞病患者的 voxotor 的 3 期随机试验。
N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14.
10
Voxelotor for the treatment of sickle cell disease.用于治疗镰状细胞病的voxelotor。
Expert Rev Hematol. 2021 Mar;14(3):253-262. doi: 10.1080/17474086.2021.1893688. Epub 2021 Mar 4.
引用本文的文献
1
Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.治疗镰状细胞病患者的当前和未来疗法。
Cells. 2024 May 16;13(10):848. doi: 10.3390/cells13100848.
2
Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease.使用伏洛昔托治疗镰状细胞病的实用指南。
J Blood Med. 2022 Nov 29;13:739-745. doi: 10.2147/JBM.S362222. eCollection 2022.
本文引用的文献
1
Effects of Renin-Angiotensin Blockade and on Kidney Function in Sickle Cell Disease.肾素-血管紧张素阻断对镰状细胞病肾功能的影响。 （你提供的原文最后有个多余的“and”，我按照正确的理解进行了翻译。）
EJHaem. 2021 Aug;2(3):483-484. doi: 10.1002/jha2.259. Epub 2021 Jul 8.
2
Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.镰状细胞贫血患者白蛋白尿的进展：一项多中心、纵向研究。
Blood Adv. 2020 Apr 14;4(7):1501-1511. doi: 10.1182/bloodadvances.2019001378.
3
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.一项针对镰状细胞病患者的 voxotor 的 3 期随机试验。
N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14.
4
Severe anemia early in life as a risk factor for sickle-cell kidney disease.生命早期的重度贫血是镰状细胞肾病的一个风险因素。
Blood. 2017 Jan 19;129(3):385-387. doi: 10.1182/blood-2016-09-738104. Epub 2016 Dec 5.
5
Sickle cell disease: renal manifestations and mechanisms.镰状细胞病：肾脏表现及机制
Nat Rev Nephrol. 2015 Mar;11(3):161-71. doi: 10.1038/nrneph.2015.8. Epub 2015 Feb 10.
6
Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia.血红蛋白尿与镰状细胞贫血患者的慢性肾病及其进展相关。
Br J Haematol. 2014 Mar;164(5):729-39. doi: 10.1111/bjh.12690. Epub 2013 Dec 12.
7
Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease.溶血和无细胞血红蛋白驱动人类疾病的内在机制。
J Clin Invest. 2012 Apr;122(4):1205-8. doi: 10.1172/JCI62972. Epub 2012 Mar 26.
8
Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.尿 L-FABP 与贫血：尿标志物在 2 型糖尿病中的不同作用。
Eur J Clin Invest. 2010 Feb;40(2):95-102. doi: 10.1111/j.1365-2362.2009.02220.x. Epub 2009 Nov 11.
9
Acute decrease in renal microvascular PO2 during acute normovolemic hemodilution.急性等容血液稀释期间肾微血管氧分压的急性降低。
Am J Physiol Renal Physiol. 2007 Feb;292(2):F796-803. doi: 10.1152/ajprenal.00206.2006. Epub 2006 Oct 31.
Zotero 插件